Veru Inc. (VERU) AI Stock Analysis

Veru Inc., originally founded as The Female Health Company and rebranded in 2017, operates as a biopharmaceutical firm focused on developing treatments for critical medical conditions including COVID-19, breast cancer, and prostate cancer. Its commercial portfolio features FC2, an internal female condom designed to prevent unintended pregnancy and sexually transmitted infections, and Entadfi, an oral capsule for urinary tract symptoms. The company's clinical pipeline includes Enobosarm in phase III clinical trials for AR+ ER+ HER2- metastatic breast cancer, Sabizabulin in phase 2b trials for breast cancer and phase 3 for metastatic castration-resistant prostate cancer, and VERU-100.

Revenue moved from $42.6M in FY2020 to $61.3M in FY2021 before dropping to $39.4M in FY2022 and $16.3M in FY2023, followed by a slight rebound to $16.9M in FY2024. Over the five years from FY2019 to FY2024, revenue recorded a CAGR of -11.9%. Gross margin declined from 72.3% in FY2020 and 78.2% in FY2021 down to 34.7% in FY2024. Net income shifted from -$19.0M in FY2020 to a profit of $7.4M in FY2021, followed by losses of -$83.8M in FY2022, -$93.2M in FY2023, and -$37.8M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue growth was 18.3% year-over-year.

As of June 30, 2026, Veru held $23.9M in cash and short-term investments against total debt of $2.7M, yielding net cash of $21.2M. Total assets stood at $37.0M and shareholders' equity was $28.4M, supported by a current ratio of 4.42 and a debt-to-equity ratio of 0.09. Operating cash flow in FY2024 was -$21.7M, while free cash flow was -$21.8M. In FY2025, capital expenditures were $1,083, and its 5-year share count change was -71.2%.

At a last close of $2.30 on October 16, 2026, Veru carried a market cap of $39.2M and an enterprise value of $18.8M. The stock trades at a forward P/E of 117.6x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 3.1x versus the peer median of 4.1x, and its EV/EBITDA is 42.9x compared to the peer median of 12.0x. Over the past year, Veru returned -44.8%, trailing the S&P 500 return of 16.8%, while its 5-year return of -97.3% significantly lagged the benchmark gain of 83.0%.

Wall Street coverage consists of 3 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $25.67, representing a premium of 1015.9% over the last close of $2.30. For the current fiscal year ending September 30, 2026, the EPS estimate is -$0.87, representing expected growth of 18.7%. For the next fiscal year, 3 analysts project an EPS of -$1.00. Veru has beaten EPS estimates in each of the last 4 quarters.

This page is an AI-written research summary of Veru Inc. (VERU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VERU income statement, VERU balance sheet, VERU key metrics, VERU analyst forecast, VERU chart. See the VERU stock overview for the latest quote and news.